Barbara Y. Chan - May 31, 2024 Form 3 Insider Report for Omega Therapeutics, Inc. (OMGA)

Role
Chief Accounting Officer
Signature
/s/ Barbara Y. Chan
Stock symbol
OMGA
Transactions as of
May 31, 2024
Transactions value $
$0
Form type
3
Date filed
5/31/2024, 04:49 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OMGA Common Stock 37.7K May 31, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OMGA Stock Option (Right to Buy) May 31, 2024 Common Stock 44.7K $2.57 Direct F1
holding OMGA Stock Option (Right to Buy) May 31, 2024 Common Stock 87.4K $5.67 Direct F2
holding OMGA Stock Option (Right to Buy) May 31, 2024 Common Stock 50K $10.34 Direct F3
holding OMGA Stock Option (Right to Buy) May 31, 2024 Common Stock 20K $5.27 Direct F4
holding OMGA Stock Option (Right to Buy) May 31, 2024 Common Stock 20K $6.46 Direct F5
holding OMGA Stock Option (Right to Buy) May 31, 2024 Common Stock 40K $3.59 Direct F6
holding OMGA Stock Option (Right to Buy) May 31, 2024 Common Stock 60K $3.02 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested.
F2 The option vests and becomes exercisable with respect to 25% of the underlying shares on March 26, 2022 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on March 26, 2025, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
F3 The option vests and becomes exercisable with respect to 25% of the underlying shares on March 9, 2023 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on March 9, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
F4 The option vests and becomes exercisable with respect to 25% of the underlying shares on October 27, 2023 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on October 27, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
F5 The option vests and becomes exercisable with respect to 25% of the underlying shares on February 29, 2024 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 28, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
F6 The option vests and becomes exercisable with respect to 25% of the underlying shares on February 7, 2025, and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 7, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
F7 The option vests and becomes exercisable with respect to 50% of the underlying shares on October 9, 2024 and the remaining 50% of the underlying shares shall vest on April 9, 2025, thereafter such that the option will become fully vested and exercisable on Aprill 9, 2025, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney